Keichiro Mihara
Department of Haematology and Oncology
Research Institute for Radiation Biology and Medicine
Hiroshima University
1-2-3 Kasumi
Japan
Name/email consistency: high
- Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Mihara, K., Yanagihara, K., Takigahira, M., Kitanaka, A., Imai, C., Bhattacharyya, J., Kubo, T., Takei, Y., Yasunaga, S., Takihara, Y., Kimura, A. Br. J. Haematol. (2010)
- Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. Mihara, K., Yanagihara, K., Takigahira, M., Imai, C., Kitanaka, A., Takihara, Y., Kimura, A. J. Immunother. (2009)
- Genetic and epigenetic alterations in myelodysplastic syndrome. Mihara, K., Takihara, Y., Kimura, A. Cytogenet. Genome Res. (2007)
- Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Mihara, K., Chowdhury, M., Nakaju, N., Hidani, S., Ihara, A., Hyodo, H., Yasunaga, S., Takihara, Y., Kimura, A. Blood (2006)